Guideline Panel Meeting: Recurrent Urinary Tract Infection (2018)

September 26, 2018 to September 27, 2018

The purpose of the Guideline Panel is to provide clinicians with evidence- and consensus-based principles and strategies for the diagnosis and management of recurrent urinary tract infection based on the current state of both clinical practice and the medical literature. There currently exists gaps in knowledge surround both how best to diagnose and manage such a condition. There exists inconsistency in practice patterns, which provides an area for improvement of patient care.

Target Audience

Urologists
Non-Urologist (MD or DO)

Learning Objectives

After particpating in this activity, participants will be able to:

  • Expand and update urology knowledge base
  • Analyze clinical skills and patient care methods towards improving their quality
  • Identify methods to improve teaching skills from familiarity with the most recent information and its clinical application
  • Demonstrate written communication skills from exposure to peer review of written materials Implement improved critical thinking skills
Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Course opens: 
09/26/2018
Course expires: 
09/27/2021
Event starts: 
09/26/2018 - 8:00am
Event ends: 
09/27/2018 - 12:30pm
Rating: 
0

Day 1

  • 7:30am                 Breakfast
  • 8:00am                 Welcome & Introductions                                                                   
  • 8:10am                 Conflict of Interest Disclosures and Panel Responsibilities            
  • 8:30am                 Guidelines Stages Overview                                                             
  • 8:45am                 Categorizing Guidelines Statements                                                      
  • 9:15am                 Evidence Report Overview                                                                                      
  • 10:00am               Evidence Report Discussion/Statement Development              
  • 10:30am               Break (10 min)                                                                  
  • 12:30pm               Lunch
  • 1:00pm                 Guideline Statement Development                                                 
  • 2:45pm                 Break (10 min)
  • 4:30pm                 Recap and Day 2 Agenda                                                                         
  • 4:45pm                 Shuttle Departs AUA to hotel                                                      
  • 6:00pm                 Shuttle departs from hotel to dinner
     

Day 2

  • 8:00am                 Breakfast
  • 8:30am                 Drafting Guideline Statements CONT’D                                               
  • 10:30am               Break (10 min)
  • 11:45am               Discussion of Diagnostic/ Treatment Algorithm                               
  • 12:15pm               Next Steps                                                                                                
  • 12:30pm               Meeting Adjourned
AUA Headquarters
Linthicum, MD
United States
NameCompanyRoleFinancial
Jennifer Anger, MD - Guideline ChairBoston ScientficScientific study or trial; otherYes
 AMSScientific study or trialYes
Victor Nitti, MD - Chair, Office of EducationAstellasScientific study or trialNo
 AllerganHealth Publishing; Scientific study or trialNo
 Serenity PharmaceuticalsInvestment InterestYes
 MedtronicScientific study or trialNo
Michael Abern - Chair COI Review Work GroupDept. of Defence Prostate Cancer Research ProgramScientific study or trial;Consultant or AdvisorYes
 American Urological Assoc.Consultant or AdvisorYes
Erin Krikby - AUA StaffNothing to Disclose  

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation

Accreditation Period

Course opens: 
09/26/2018
Course expires: 
09/27/2021
Please login or register to take this course.

This activity is restricted to members of the Recurrent Urinary Tract Infection Panel.